Spatio-Temporal Analysis of the Hepatitis B Prevalence in Irani-an Blood Donors from 2000 to 2016 at National and Provincial Level
Background: High risk blood transfusions can cause a lot of financial and psychological burden to the community. The prevalence of Hepatitis B is useful for evaluating the blood products' safety and donor selection methods. We aimed to predict the prevalence of hepatitis B in Iranian blood donors from 2000-2016.
Methods: Positive cases of hepatitis B from 2006 to 2014 were collected from Iranian Blood Transfusion Organization. This database was classified according to the age, provinces, and type of donation. Data was not existed in all subnational levels and all years, therefore, for predicting the hepatitis B prevalence, two separate, Spatio-temporal and mixed model (GLMM) were developed.
Results: At the national level, the hepatitis B prevalence declined from 0.69 (0.51 to 0.90) in 2000 to 0.27 (0.21 to 0.33) in 2016. In first-time, regular, and repeated donors, this prevalence declined from 2.31 (1.74 to 2.31), 0.26 (0.19 to 0.34), and 0.51 (0.38 to 0.68) in 2000 to 0.87 (0.69 to 1.09), 0.09 (0.07 to 0.12), and 0.19 (0.14 to 0.24) in 2016. At the provincial level, the highest and lowest prevalence in 2016 was observed in North Khorasan and Gilan. With increasing age, the average prevalence of hepatitis B, increased.
Conclusion: Prevalence of hepatitis B in Iranian blood donors has been reduced significantly over 17 years, but still new cases of hepatitis B are reported. By precise monitoring the donor selection process and implementing more sensitive laboratory screening, we can reduce the risk of new infectious agents.
2. Buseri FI, Muhibi MA, Jeremiah ZA (2009). Sero-epidemiology of transfusion-transmissible infectious diseases among blood donors in Osogbo, south-west Nigeria. Blood Transfus, 7(4):293-9.
3. La Torre G, Saulle R (2016). Risk factors from HBV infection among blood donors: A systematic review. Asian Pacific J Trop Biomed, 6:344-349.
4. Pourfathollah AA (2014). Changes in frequency of HBV, HCV, HIV and syphilis infections among blood donors in Tehran province 2005–2011. Arch Iran Med, 17(9):613-20.
5. Bhawani Y, Rao PR, Sudhakar V (2010). Seroprevalence of transfusion transmissible infections among blood donors in a tertiary care hospital of Andhra Pradesh. Biol Med, 2:45-48.
6. Babanejad M, Izadi N, Najafi F, Alavian SM (2016). The HBsAg Prevalence among blood donors from Eastern Mediterranean and Middle Eastern countries: a systematic review and meta-Analysis. Hepat Mon, 16 (3): e35664.
7. Mohammadi Y, Parsaeian M, Farzadfar F, Kasaeian A, Mehdipour P, Sheidaei A, Mansouri A, Moghaddam SS, Djalalinia S, Mahmoudi M (2014). Levels and trends of child and adult mortality rates in the Islamic Republic of Iran, 1990-2013; protocol of the NASBOD study. Arch Iran Med , 17 (3):176-81.
8. Peykari N, Ghajarieh Sepanlou S, Djalalinia S, Kasaeian A, Parsaeian M, Ahmadvand A, Koohpayehzadeh J, Damari B, Jamshidi HR, Larijani B, Farzadfar F (2014). National and Sub-national Prevalence, Trend, and Burden of Metabolic Risk Factors (MRFs) in Iran: 1990 – 2013, Study Protocol. Arch Iran Med, 17(1):54-61.
9. Ashrafi E, Mohammadi S-F, Fotouhi A, Lashay A, Asadi-lari M, Mahdavi A, Jabbarvand M, Sobhani S, Farzadfar F (2014). National and Sub-national Burden of Visual Impairment in Iran1990-2013; Study Protocol. Arch Iran Med , 17(12):810-5.
10. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The lancet, 380:2095-2128.
11. Busch M (2000). HIV, HBV and HCV: new developments related to transfusion safety. Vox sang, 78 Suppl 2:253-256.
12. O'Brien SF, Xi G, Fan W, Yi QL, Fearon MA, Scalia V, Goldman M (2008). Epidemiology of hepatitis B in Canadian blood donors. Transfusion, 48(11):2323-2330.
13. Bajubair MA, Elrub AA, Bather G (2008). Hepatic viral infections in Yemen between 2000--2005. Saudi Med J, 29(6):871-874.
14. Phikulsod S, Oota S, Tirawatnapong T, Sakuldamrongpanich T, Chalermchan W, Louisirirotchanakul S, Tanprasert S, Chongkolwatana V, Kitpoka P, Phanuphak P (2009). One‐year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations. Transfusion, 49(6):1126-1135.
15. Manzoor I, Hashmi N, Daud S, Ajmal S, Fatima H, Rasheed Z, Syed S (2009). Seroprevalence of transfusion transmissible infections (TTIS) in blood donors. Biomedica, 25:154-8.
16. Ali SA, Donahue RM, Qureshi H, Vermund SH (2009). Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infec Dis, 13(1):9-19.
17. Redwan N, Ahmed M, Barnawi M (2012). Prevalence study of Hepatitis B virus (HBV) infection by serological techniques in Jeddah, Saudi Arabia. Life Sci J, 9:5442-8.
18. Amini Kafi‐abad S, Rezvan H, Abolghasemi H, Talebian A (2009). Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion, 49(10):2214-2220.
19. Sajad Alizadeh IP, Kouresh Sayehmiri, Reza Pakzad, Parisa Darvishi (2014). Prevalence of Hepatitis B among Blood Donors in Iran: A Systematic Review and Meta-analysis . Asian J. Biol. Sci., 7:35-46.
20. Mirrezaie SM, Saber HR, Hajibeigi B, Salekmoghaddam E, Abbasian A, Alavian SM (2014). Impact of HBV vaccination on prevalence of hepatitis B virus infection among volunteer blood donors in Tehran-Iran. Shiraz E-Medical Journal, 15.
21. Porolajal J, Majdzadeh R (2009). Prevalence of chronic Hepatitis B infection in Iran. Iranian Journal of Epidemiology, 4:1-8.
22. WHO (2017). Guidelines on hepatitis b and c testing.:36-44. https://apps.who.int/iris/bitstream/handle/10665/254621/9789241549981-eng.pdf
23. Candotti D, Allain J-P (2009). Transfusion-transmitted hepatitis B virus infection. J Hepatol, 51(4):798-809.
24. Rezaei N, Amini‐Kafiabad S, Maghsudlu M, Abolghasemi H (2016). Risk factor analysis of hepatitis C virus seropositivity in Iranian blood donors: a case‐control study. Transfusion, 56(7):1891-1898.
|Issue||Vol 50 No 9 (2021)|
|Hepatitis B Prevalence Blood donors|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|